Business · 30/08/1994Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for Effexor Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially announced the regulatory review period for the patent extension of Effexor, a prescription medication, in accordance with federal regulations and law requirements.
Original source language: Federal Register — Health and Human ServicesOpen original release →